Verona Pharma PLC
VRNA68.705USD
+3.245+4.96%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
46.51BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Verona Pharma PLC Unternehmen
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Unternehmensinformationen
Unternehmens-codeVRNA
Name des UnternehmensVerona Pharma PLC
IPO-datumMar 30, 2005
Gegründet am2005
CEODr. David S. Zaccardelli
Anzahl der mitarbeiter209
WertpapierartDepository Receipt
GeschäftsjahresendeMar 30
AddresseRiverside
StadtLONDON
BörseNASDAQ Global Market Consolidated
LandUnited Kingdom
PostleitzahlSE1 2RE
Telefon442032834200
Websitehttps://www.veronapharma.com/
Unternehmens-codeVRNA
IPO-datumMar 30, 2005
Gegründet am2005
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. David S. Zaccardelli
Dr. David S. Zaccardelli
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
11.51M
+1.80K%
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Chief Financial Officer
Chief Financial Officer
10.60M
+4.02K%
Ms. Claire Louise Poll
Ms. Claire Louise Poll
General Counsel
General Counsel
541.81K
--
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Non-Executive Independent Director
Non-Executive Independent Director
74.44K
+700.00%
Dr. Mahendra G. Shah, Ph.D.
Dr. Mahendra G. Shah, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
73.08K
+700.00%
Ms. Lisa Deschamps
Ms. Lisa Deschamps
Non-Executive Independent Director
Non-Executive Independent Director
70.32K
+700.00%
Mr. Michael Austwick
Mr. Michael Austwick
Non-Executive Director
Non-Executive Director
--
--
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Christina Ackermann
Ms. Christina Ackermann
Non-Executive Director
Non-Executive Director
--
--
Dr. Martin William Edwards, M.D.
Dr. Martin William Edwards, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. David S. Zaccardelli
Dr. David S. Zaccardelli
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
11.51M
+1.80K%
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Chief Financial Officer
Chief Financial Officer
10.60M
+4.02K%
Ms. Claire Louise Poll
Ms. Claire Louise Poll
General Counsel
General Counsel
541.81K
--
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Non-Executive Independent Director
Non-Executive Independent Director
74.44K
+700.00%
Dr. Mahendra G. Shah, Ph.D.
Dr. Mahendra G. Shah, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
73.08K
+700.00%
Ms. Lisa Deschamps
Ms. Lisa Deschamps
Non-Executive Independent Director
Non-Executive Independent Director
70.32K
+700.00%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionäre
Update-Zeit: Fri, Mar 28
Update-Zeit: Fri, Mar 28
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Zaccardelli (David S)
13.55%
Hahn (Mark W)
12.48%
Perceptive Advisors LLC
7.52%
New Enterprise Associates (NEA)
4.81%
Frazier Life Sciences Management, L.P.
3.98%
Other
57.67%
Aktionärsstatistik
Aktionäre
Anteil
Zaccardelli (David S)
13.55%
Hahn (Mark W)
12.48%
Perceptive Advisors LLC
7.52%
New Enterprise Associates (NEA)
4.81%
Frazier Life Sciences Management, L.P.
3.98%
Other
57.67%
Art
Aktionäre
Anteil
Individual Investor
35.16%
Investment Advisor/Hedge Fund
22.11%
Hedge Fund
21.55%
Investment Advisor
15.58%
Private Equity
11.64%
Venture Capital
7.78%
Research Firm
2.44%
Family Office
1.04%
Bank and Trust
0.28%
Institutionelle Beteiligung
Update-Zeit: Tue, Mar 4
Update-Zeit: Tue, Mar 4
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
341
98.98M
116.47%
+16.60M
2024Q4
326
71.46M
84.46%
-16.29M
2024Q3
290
72.06M
88.66%
-13.37M
2024Q2
265
71.81M
88.57%
-10.49M
2024Q1
244
72.12M
89.24%
-7.07M
2023Q4
230
69.67M
87.15%
-7.79M
2023Q3
210
67.04M
84.35%
-7.14M
2023Q2
205
65.57M
82.53%
-8.85M
2023Q1
188
68.22M
86.63%
-3.18M
2022Q4
162
65.88M
87.36%
-542.66K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Zaccardelli (David S)
11.51M
13.55%
+10.91M
+1.80K%
Mar 01, 2025
Hahn (Mark W)
10.60M
12.48%
+10.34M
+4.02K%
Mar 01, 2025
Perceptive Advisors LLC
6.39M
7.52%
+76.17K
+1.21%
Dec 31, 2024
New Enterprise Associates (NEA)
4.08M
4.81%
-1.50M
-26.86%
Jan 16, 2025
Frazier Life Sciences Management, L.P.
3.38M
3.98%
--
--
Dec 31, 2024
Ali (Behbahani)
3.19M
3.76%
+3.19M
--
Jan 16, 2025
Eventide Asset Management, LLC
3.13M
3.69%
+706.28K
+29.11%
Dec 31, 2024
Maverick Capital, Ltd.
3.13M
3.68%
-1.09M
-25.79%
Dec 31, 2024
Wellington Management Company, LLP
3.03M
3.56%
+1.15M
+61.03%
Dec 31, 2024
Vivo Capital, LLC
2.28M
2.69%
-1.27M
-35.66%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Sun, Apr 6
Update-Zeit: Sun, Apr 6
Name
Anteil
AdvisorShares Dorsey Wright ADR ETF
6.2%
ALPS Medical Breakthroughs ETF
4.7%
ProShares Ultra Nasdaq Biotechnology
0.5%
First Trust IPOX Europe Equity Opportunities ETF
0.49%
Invesco Nasdaq Biotechnology ETF
0.49%
iShares Biotechnology ETF
0.3%
Goldman Sachs Innovate Equity ETF
0.16%
Eventide US Market ETF
0.09%
Fidelity Nasdaq Composite Index ETF
0.01%
First Trust Long/Short Equity ETF
0%
Mehr Anzeigen
AdvisorShares Dorsey Wright ADR ETF
Anteil6.2%
ALPS Medical Breakthroughs ETF
Anteil4.7%
ProShares Ultra Nasdaq Biotechnology
Anteil0.5%
First Trust IPOX Europe Equity Opportunities ETF
Anteil0.49%
Invesco Nasdaq Biotechnology ETF
Anteil0.49%
iShares Biotechnology ETF
Anteil0.3%
Goldman Sachs Innovate Equity ETF
Anteil0.16%
Eventide US Market ETF
Anteil0.09%
Fidelity Nasdaq Composite Index ETF
Anteil0.01%
First Trust Long/Short Equity ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten